Beta-site amyloid-precursor-protein cleaving enzyme 1 (BACE1) is considered as a potential drug target for therapeutic intervention in Alzheimer’s disease (AD) for years. Here, BACE1 is linked to early-onset autosomal dominant Alzheimer disease.